Photo 2 of 4The right Alpha-GPC if NOW's brand pedigree beats Nutricost's dose density for you.
NOW Foods is one of the few supplement brands that earned consumer trust the long way: 50+ years of family ownership, in-house third-party testing programs before the industry made that normal, NSF-registered facilities, and a clean regulatory track record. Their Alpha-GPC bottle is the trusted-brand answer to Nutricost's budget-tier dominance — same active compound (Alpha-glycerylphosphorylcholine, the choline donor that crosses the blood-brain barrier), but at half the per-cap dose (300 mg vs Nutricost's 600 mg) and roughly twice the per-active-mg cost. The honest framing isn't 'NOW vs Nutricost' as if one is fake — it's 'do you want the brand pedigree premium, or the dose-density savings?' Six weeks of testing both and reading the trial literature, here's where NOW's Alpha-GPC actually wins and where it loses.
Alpha-GPC's RCT base is solid: Ziegenfuss 2008 documented acute cognition + power-output effects at 600 mg; Bellar 2015 replicated the lower-body isometric strength uplift at 600 mg/day for 6 days; Parker 2015 confirmed cognitive function effects at 600 mg. NOW Foods' per-cap dose (300 mg) is half the trial dose, so single-cap dosing puts you below the validated range. Two-cap dosing puts you at the trial floor. The active compound matches the literature — the bottle's per-cap math just shifts the protocol from 1 cap to 2.
Alpha-glycerylphosphorylcholine crosses the blood-brain barrier intact, donates choline to acetylcholine synthesis (the primary excitatory neurotransmitter for attention + motor unit recruitment), and contributes phosphatidylcholine to membrane integrity. The mechanism is biochemically specific to the focus + power-output endpoints the marketing promises — no hand-waving 'general brain support' framing. Among natural nootropics, only L-Theanine has comparable mechanism specificity to cognitive endpoints.
Bellar 2015 measured a +14% uplift in lower-body isometric mid-thigh pull force at 600 mg/day. Ziegenfuss 2008 showed acute cognition improvements within 60 min of dosing. Effect sizes are clinically meaningful and replicated. NOW's 300 mg per cap requires 2-cap dosing to hit those effect sizes — single-cap response will be proportionally smaller, somewhere in the 5-8% effect range based on dose-response extrapolation.
$18/month at 2 caps/day = $0.30 per 300 mg cap = $0.60 per 600 mg trial-dose serving. Nutricost (#3) lands at $0.23 per 600 mg cap — roughly half the per-mg cost. NOW's premium is the brand pedigree + NSF-registered facility + in-house QC. Reasonable at the trusted-brand tier; clearly more expensive than the budget tier.
Alpha-GPC is NCAA-legal and WADA-legal. NOW Foods' facility is NSF-registered with in-house and contracted third-party testing for identity, potency, heavy metals, microbials, and adulterants. The Lee 2021 observational stroke-risk signal applies category-wide, not bottle-specific — use Alpha-GPC for cycles, not continuously for years. NOW's QC discipline reduces the rare risk of cross-contamination from shared GMP facilities.
“Supports brain function and mental focus.”
True at the trial dose (600 mg = 2 caps). Ziegenfuss 2008 and Parker 2015 both documented acute cognition improvements at 600 mg. At 1 cap (300 mg) the effect is proportionally smaller. The claim is real but dose-dependent — single-cap users are below the validated range.
“Highly bioavailable choline source.”
Alpha-GPC crosses the blood-brain barrier intact and donates choline directly to acetylcholine synthesis. More bioavailable to brain tissue than choline bitartrate or CDP-choline by most published comparisons. Verified by mechanistic biochemistry, not just marketing.
“Manufactured in our NSF-registered facility.”
NOW Foods' Bloomingdale facility is NSF-registered and publishes its certifications openly. Verifiable via the NSF database. One of the cleanest QC operations in the consumer supplement industry.
“Non-GMO, soy-free.”
Both certifications are on-label and verifiable. Standard at the NOW Foods tier.
“Promotes healthy cognitive function.”
True directionally — Alpha-GPC's choline-donor mechanism is the same one your brain uses for acetylcholine synthesis, so supporting cognition is the literal biochemical effect. The asterisk is dose — 'healthy cognitive function' is a structure/function claim that's vague enough to be defensible at any dose, but the trial-measured cognition effect requires 600 mg.
Nutricost's 600 mg per cap is dose-density optimized: one cap, hit the trial dose, done. NOW's 300 mg per cap is titration-optimized: 1 cap = test the substrate at half dose, 2 caps = trial-dose protocol, no capsule-splitting required. For first-time Alpha-GPC users who want to ramp from 300 to 600 mg over a week, NOW's bottle gives you that without dose-mathematics. For users who've already validated they respond and want trial-dose simplicity, Nutricost is the better fit. The bottles serve different decision contexts at different per-mg costs.
The NOW Foods QC story isn't marketing: NSF-registered facility, in-house labs running identity + potency + heavy metals + microbial assays per batch, plus contracted third-party verification. Most patent-tier brands match this standard; almost no budget-tier brand does. The relevant question for the reader is whether QC pedigree justifies a 2x per-mg cost vs Nutricost. If you've had bad experiences with low-tier supplement QC, or if you're sensitive to cross-contamination (athletic drug testing, food sensitivities), the answer is yes. If you're a typical consumer running short cycles, Nutricost is the cheaper rational choice.
The split-protocol that gets the most out of NOW's 300 mg cap: 1 cap (300 mg) with breakfast as a daily acetylcholine substrate baseline, then 1 additional cap (total 600 mg) 30-45 min before training on workout days. This protocol matches the Bellar 2015 daily-dosing pattern AND captures the pre-training acute cognition + power-output effect Ziegenfuss 2008 documented. 60 caps last ~6 weeks at this cadence — about one training cycle. Cycle off for 4 weeks after each 6-8 week run to address the Lee 2021 long-term-use concern.
The Lee 2021 Korean health-insurance observational study flagged a small stroke-risk signal in long-term Alpha-GPC users. The study is observational (not RCT), the population was post-stroke patients on multiple medications, and the signal hasn't been replicated in healthy-adult RCTs — so the risk is small and uncertain. The cautious protocol that costs nothing: cycle 8-12 weeks on, 4 weeks off. This addresses the long-term concern AND prevents the choline-receptor desensitization that flattens response in continuous users. For pre-training cognition + power output, 8-week cycles are the natural rhythm anyway.
Alpha-GPC and L-Theanine have orthogonal mechanisms — acetylcholine for attention + motor unit recruitment, alpha-wave EEG for relaxed alertness. They don't compete; they compound. The full pre-deep-work stack: NOW Alpha-GPC 600 mg + L-Theanine 200 mg + caffeine 100 mg, 30-45 min before the block. Three single-ingredient bottles, full dose control, no proprietary blend. Cheaper and more effective per dollar than any multi-ingredient nootropic blend on the market — including Mind Lab Pro (#9), which bundles these ingredients at sub-trial doses for $69/month.
NOW Foods Alpha-GPC 300 mg sits in a specific spot in the Alpha-GPC market: the brand pedigree premium without the patent-tier markup. You pay roughly 2x Nutricost's per-mg cost for NSF-registered facility QC, in-house third-party labs, and 50+ years of clean regulatory track record. For users who specifically value brand pedigree — typically because they've had bad experiences with low-tier supplement QC, or because they're stacking multiple supplements long-term and want each bottle from a name they trust — this is the rational choice. The 300 mg per cap is the dose-density trade-off. Nutricost's 600 mg per cap is one-and-done at the trial dose; NOW's 300 mg requires 2 caps. For titration-conscious buyers or users who want to test at half-dose first, NOW's smaller capsule is the feature. For trial-dose simplicity, Nutricost is the better fit. The 8.2 'consider' score reflects this: NOW's bottle is genuinely excellent at what it does, but it doesn't dominate Nutricost on the criteria most buyers actually optimize for (price-per-active-mg, dose-per-cap, trial-dose convenience). Buy it if you specifically want NOW. Buy Nutricost if you want maximum Alpha-GPC per dollar.
Affiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Budget-tier upgrade for dose density — 600 mg per cap (matches Bellar 2015 trial dose in 1 cap) at $14/month. Half the per-mg cost of NOW; less brand pedigree. The right pick if dollar-per-active-mg is your decision criterion.
See it on the list →Different active for a different goal — Suntheanine L-Theanine for the acute focus + relaxed alertness layer. Stacks cleanly with Alpha-GPC pre-training for the full attention + motor-unit + alpha-wave protocol.
See it on the list →Cumulative neuroplasticity pick — NGF upregulation + myelin sheath support. Different timeline (16 weeks for measurable cognition vs Alpha-GPC's 30-60 min acute effect). Pair with Alpha-GPC for the acute + cumulative compound stack.
See it on the list →600 mg Alpha-GPC pre-exercise significantly increased peak bench-press force production and growth hormone response vs placebo. The foundational acute cognition + power-output trial that anchors the Alpha-GPC evidence base.
Alpha-GPC at 600 mg improved cognitive function, mood, and lower-body force production vs placebo. Confirmed the dual cognition + athletic-performance signal at the same trial dose as Ziegenfuss 2008.
Alpha-GPC at 600 mg/day for 6 days produced a significant +14% increase in lower-body isometric mid-thigh pull force vs placebo. The replication trial that validated the power-output effect across a multi-day dosing protocol.
L-Theanine 50-200 mg measurably increased alpha-wave EEG activity within 30-45 min. Establishes the mechanism for stacking L-Theanine with Alpha-GPC — orthogonal pathways, compounding focus effect.
